Salvia BioElectronics raises $60M Series B for implantable VNS migraine prevention — largest European migraine device round
Summary
Salvia BioElectronics raised $60M in a Series B to complete clinical development and prepare commercial launch of their SALVIA implantable VNS system for chronic migraine. The Netherlands company targets patients who have failed ≥3 preventive medications including CGRP antibodies — the treatment-refractory population where no device options currently exist. Total Salvia funding reaches $95M including prior rounds.
Why it matters
Salvia's $60M is the largest single round ever raised for a device-based migraine prevention company, reflecting investor conviction that treatment-refractory chronic migraine represents a clearly defined, large, and commercially addressable patient population for an implantable neuromodulation device.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial